Tarlatamab-Imdelltra’s domestic launch time, approval status and sales channel description

Tarlatamab (trade name Imdelltra) is a new type of targeted immunotherapy monoclonal antibody, mainly used for the treatment of specific types of tumors. Its mechanism of action is by recognizing tumor-related antigens and activating T cells, thereby achieving precise killing of tumor cells. The drug has innovative immunomodulatory effects and provides a new treatment option for patients with advanced or refractory tumors, especially for patients with limited efficacy of standard therapies.

In terms of domestic marketing status, talatumumab has not yet been officially approved for marketing. Recently, the drug has submitted a marketing application to the State Food and Drug Administration and is expected to be approved and enter the domestic market in the future. Since it is not yet on the market, talatumumab cannot be included in domestic medical insurance reimbursement for the time being. If patients want to use it, they still need to wait for the approval of the drug and the introduction of relevant policies.

In overseas markets, talatumumab has been approved by the USFDA in 2024 year5 months. There are two main specifications available overseas: 1mg and 10mg, with prices of approximately RMB2.5 yuan and 14.8 yuan respectively. There is currently no related generic version of this drug, and all sales are original drugs. Overseas drugs are mainly obtained through hospital specialist supply or authorized pharmacy channels to ensure drug quality and safety.

Overall, talatumumab is a new drug waiting to be launched in China and has significant clinical application potential. While waiting for the market, patients should pay attention to the latest approval information from the National Food and Drug Administration and choose an appropriate treatment plan under the guidance of clinicians. In the future, with the gradual improvement of domestic launches and medical insurance policies, talatumumab is expected to provide safe and standardized targeted treatment options for patients with more indications.

Reference materials:https://www.drugs.com/